Showing results (1111-1120 of 2,811) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|September 3, 2024
Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical reviewMarco Solmi, Alessandro Miola, Federico Capone, et al.Expert Opinion on Drug Safety|June 18, 2024
Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS databaseYating Qian, Xinxia Zhao, Danyi Liu, et al.Expert Opinion on Drug Safety|June 20, 2024
Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS databaseXiaochen Wan, Shuohan Zhang, Cheng Jiang, et al.Expert Opinion on Drug Safety|May 31, 2024
Immune checkpoint inhibitors and neurotoxicity: a focus on diagnosis and management for a multidisciplinary approachDesirèe Speranza, Mariacarmela Santarpia, Francesco Luppino, et al.Expert Opinion on Drug Safety|July 25, 2024
Cytokine release syndrome associated with immune checkpoint inhibitors: a pharmacovigilance study based on spontaneous reports in FAERSXin Xi, Xida Yan, Ying Chen, et al.Expert Opinion on Drug Safety|July 6, 2024
A real-world pharmacovigilance study of FDA adverse event reporting system events for atogepantHeli Wen, Yitian Ding, Feichi ChenExpert Opinion on Drug Safety|July 5, 2024
PARP inhibitor-related acute renal failure: a real-world study based on the FDA adverse event reporting system databaseXiayang Ren, Ping Sun, Yanfeng WangExpert Opinion on Drug Safety|August 23, 2023
Ocular toxicities associated with antibody drug conjugates and immunotherapy in oncology: clinical presentation, pathogenesis, and management strategiesFarah Raheem, Nada Alsuhebany, Erin Hickey Zacholski, et al.Expert Opinion on Drug Safety|August 23, 2023
Urinary tract infection following the use of BTK inhibitors: a real-world analysis of post-marketing surveillance dataHui Yang, Zhexin Ding, Zhuoling AnExpert Opinion on Drug Safety|August 23, 2023
Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance studyXin Lai, Qing Wan, Shou-Feng Jiao, et al.Pageof 282